Institution
Central Drug Research Institute
Facility•Lucknow, Uttar Pradesh, India•
About: Central Drug Research Institute is a facility organization based out in Lucknow, Uttar Pradesh, India. It is known for research contribution in the topics: Leishmania donovani & Brugia malayi. The organization has 4357 authors who have published 7257 publications receiving 143871 citations. The organization is also known as: Central Drug Research Institute, Lucknow & CDRI.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: C cucurbitacin B (CuB), a single bioactive triterpenoid compound, inhibits both DNMTs and HDACs starting at a very low dose of 60 nmol/L in NSCLC H1299 cells, providing new insight into the CuB-mediated epigenetic alterations and its chemotherapeutic effects on lung cancer.
Abstract: Non-small cell lung cancer (NSCLC) represents almost 85% of total diagnosed lung cancer. Studies have shown that combination of DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors is effective against various cancers, including lung cancer. However, optimizing the synergistic dose regime is very difficult and involves adverse side effects. Therefore, in this study, we have shown that cucurbitacin B (CuB), a single bioactive triterpenoid compound, inhibits both DNMTs and HDACs starting at a very low dose of 60 nmol/L in NSCLC H1299 cells. The CuB-mediated inhibition of DNMTs and HDACs in H1299 cells leads to the reactivation of key tumor suppressor genes (TSG) such as CDKN1A and CDKN2A, as well as downregulation of oncogenes c-MYC and K-RAS and key tumor promoter gene (TPG), human telomerase reverse transcriptase (hTERT). The upregulation of TSGs and downregulation of TPG were consistently correlated with the alterations in their promoter methylation and histone modifications. This altered expression of TPG and TSGs is, at least in part, responsible for the inhibition of cellular proliferation and induction of cellular apoptosis in NSCLC. Furthermore, CuB treatment significantly inhibited the tumor incidence and multiplicity in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in A/J mice, which was associated with the induction of apoptosis and inhibition of hyperproliferation in the lung tissues. Together, our study provides new insight into the CuB-mediated epigenetic alterations and its chemotherapeutic effects on lung cancer.
48 citations
••
TL;DR: The results indicate the presence of immunostimulatory and protective molecules in F2 sub fraction which may further be exploited for the development of a vaccine against VL, hitherto an unrealized goal.
48 citations
••
TL;DR: SYM treatment prevented HFr induced mRNA expression of hepatic PGC-1α/β and also its target transcription factors which was accompanied with recovery in insulin sensitivity and reduced propensity towards thrombotic complications and aggravated MI-RP injury.
48 citations
••
TL;DR: It is reported for the first time that oral administration of Bacillus clausii in postmenopausal osteoporotic mice model enhances bone health, and this effect was found due to skewing of Treg-Th17 cell balance (enhanced Treg and decreased Th17 cells) in vivo.
48 citations
••
TL;DR: Synthesis of novel 4-aminoquinoline-rhodanine hybrid using inexpensive starting materials via easy to operate methodology, and their biological activity is reported.
48 citations
Authors
Showing all 4385 results
Name | H-index | Papers | Citations |
---|---|---|---|
Sanjay Kumar | 120 | 2052 | 82620 |
John A. Katzenellenbogen | 95 | 691 | 36132 |
Brajesh K. Singh | 83 | 401 | 24101 |
Gaurav Sharma | 82 | 1244 | 31482 |
Sudhir Kumar | 82 | 524 | 216349 |
Pramod K. Srivastava | 79 | 390 | 27330 |
Mohan K. Raizada | 75 | 473 | 21452 |
Syed F. Ali | 71 | 446 | 18669 |
Ravi Shankar | 66 | 672 | 19326 |
Ramesh Chandra | 66 | 620 | 16293 |
Manoj Kumar | 65 | 408 | 16838 |
Manish Kumar | 61 | 1425 | 21762 |
Anil Kumar Saxena | 58 | 310 | 10107 |
Sanjay Krishna | 56 | 624 | 13731 |
Naibedya Chattopadhyay | 56 | 242 | 9795 |